- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06574308
Clinical Evaluation of the Scopio Cell Morphology Technology (Hemascopio)
August 26, 2024 updated by: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Clinical Evaluation of the Scopio Cell Morphology Technology on Pre-classification of Blood Cells in Peripheral Blood (PB) and Bone Marrow (BM)
Digital morphology is currently expanding and developing new applications based on artificial intelligence software.
We recently published a study comparing screen validation and microscopic reading of bone marrow aspirates.
The aim of the current research will be the comparison between optical microscope reading and automatic pre-classification (AI based)
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
300
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Patrizia Chiusolo, MD
- Phone Number: +390630154206
- Email: patrizia.chiusolo@unicatt.it
Study Contact Backup
- Name: Elena Rossi, MD
- Phone Number: +390630154206
- Email: elena.rossi@unicatt.it
Study Locations
-
-
-
Roma, Italy, 00168
- Fondazione Policlinico Universitario A. Gemelli IRCCS
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
Pazienti affetti da emopatie
Description
Inclusion Criteria:
- Patients suffering from hemopathies with bone marrow aspirate assessable under the optical microscope
Exclusion Criteria:
- Patients not affected by blood disorders
- Patients suffering from hemopathies with bone marrow aspirate that cannot be assessed under the optical microscope
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Optical microscope reading and automatic pre-classification
Time Frame: 12 months
|
Comparison between optical microscope reading and automatic pre-classification (AI based)
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Patrizia Chiusolo, Fondazione Policlinico Universitario A. Gemelli, IRCCS
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
September 1, 2024
Primary Completion (Estimated)
September 1, 2025
Study Completion (Estimated)
September 1, 2025
Study Registration Dates
First Submitted
August 26, 2024
First Submitted That Met QC Criteria
August 26, 2024
First Posted (Actual)
August 27, 2024
Study Record Updates
Last Update Posted (Actual)
August 27, 2024
Last Update Submitted That Met QC Criteria
August 26, 2024
Last Verified
August 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 6901
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Blood Cancer
-
CytoMed Therapeutics Pte LtdNational University Hospital, SingaporeRecruitingCancer | Malignancy | Relapsed Cancer | Refractory CancerSingapore
-
University of Colorado, DenverChildren's Hospital ColoradoCompleted
-
Brigham and Women's HospitalHarvard Medical School (HMS and HSDM)CompletedHematopoietic/Lymphoid Cancer | Hematologic Malignancy | Blood CancerUnited States
-
PfizerCompletedCancerUnited States, Canada, Spain, Austria, Netherlands
-
Brigham and Women's HospitalNational Cancer Institute (NCI)CompletedHematopoietic/Lymphoid Cancer | Hematologic Malignancy | Blood CancerUnited States
-
Eunice Kennedy Shriver National Institute of Child...Withdrawn
-
Peking Union Medical College HospitalRecruitingStroke | Cancer- and Cancer Treatment-Related ConditionsChina
-
Myriad Therapeutics, Inc.Terminated
Clinical Trials on Blood cells classification
-
Lyell McEwin HospitalUniversity of AdelaideCompletedColorectal Neoplasms | Colorectal Polyp
-
Tuğba ŞAHİNCompletedPeriodontal Disease (Diagnosis)Turkey (Türkiye)
-
Piazza della Vittoria 14 Studio Medico - Ginecologia...RecruitingEndometriosis | Deep Endometriosis | Ovarian Endometrioma | Bowel EndometriosisItaly
-
Columbia UniversityCenters for Disease Control and Prevention; Ministry of Health, RwandaCompleted
-
Seoul National University HospitalWithdrawnPostoperative Complications | Orthopedics | Red Blood CellsKorea, Republic of
-
Ebtesama HospitalCompleted
-
University of CalgaryUnknownBone Marrow Failure Syndrome
-
Peking University Third HospitalCompletedMRI | Tennis Elbow | HyperlipidemiaChina
-
Murdoch Childrens Research InstituteCompletedHeart Defects, Congenital | Hypoplastic Left Heart Syndrome | Pediatric DisorderAustralia
-
Cerus CorporationCompletedFocus: Assess Post Infusion Viability of S303 RBCsUnited States